Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Flory T Muanda, Matthew A Weir, Lavanya Bathini, Peter G Blake, Kianna Chauvin, Stephanie N Dixon, Eric McArthur, Jessica M Sontrop, Louise Moist, Amit X Garg
Importance: At least 30 case reports have linked the muscle relaxant baclofen to encephalopathy in patients with chronic kidney disease (CKD). Objective: To compare the 30-day risk of encephalopathy in patients with CKD and newly prescribed baclofen at greater than or equal to 20 mg per day vs less than 20 mg per day. The secondary objective was to compare the risk of encephalopathy in baclofen users vs nonusers. Design, Setting, and Participants: Retrospective population-based cohort study in Ontario, Canada (2007-2018) using linked health care data...
November 9, 2019: JAMA
#2
Robert G Nelson, Morgan E Grams, Shoshana H Ballew, Yingying Sang, Fereidoun Azizi, Steven J Chadban, Layal Chaker, Stephan C Dunning, Caroline Fox, Yoshihisa Hirakawa, Kunitoshi Iseki, Joachim Ix, Tazeen H Jafar, Anna Köttgen, David M J Naimark, Takayoshi Ohkubo, Gordon J Prescott, Casey M Rebholz, Charumathi Sabanayagam, Toshimi Sairenchi, Ben Schöttker, Yugo Shibagaki, Marcello Tonelli, Luxia Zhang, Ron T Gansevoort, Kunihiro Matsushita, Mark Woodward, Josef Coresh, Varda Shalev
Importance: Early identification of individuals at elevated risk of developing chronic kidney disease (CKD) could improve clinical care through enhanced surveillance and better management of underlying health conditions. Objective: To develop assessment tools to identify individuals at increased risk of CKD, defined by reduced estimated glomerular filtration rate (eGFR). Design, Setting, and Participants: Individual-level data analysis of 34 multinational cohorts from the CKD Prognosis Consortium including 5 222 711 individuals from 28 countries...
November 8, 2019: JAMA: the Journal of the American Medical Association
#3
Ian H de Boer, Leila R Zelnick, John Ruzinski, Georgina Friedenberg, Julie Duszlak, Vadim Y Bubes, Andrew N Hoofnagle, Ravi Thadhani, Robert J Glynn, Julie E Buring, Howard D Sesso, JoAnn E Manson
Importance: Chronic kidney disease (CKD) is a common complication of type 2 diabetes that can lead to end-stage kidney disease and is associated with high cardiovascular risk. Few treatments are available to prevent CKD in type 2 diabetes. Objective: To test whether supplementation with vitamin D3 or omega-3 fatty acids prevents development or progression of CKD in type 2 diabetes. Design, Setting, and Participants: Randomized clinical trial with a 2 × 2 factorial design conducted among 1312 adults with type 2 diabetes recruited between November 2011 and March 2014 from all 50 US states as an ancillary study to the Vitamin D and Omega-3 Trial (VITAL), coordinated by a single center in Massachusetts...
November 8, 2019: JAMA: the Journal of the American Medical Association
#4
Sri Lekha Tummalapalli, Michelle M Estrella
No abstract text is available yet for this article.
November 8, 2019: JAMA: the Journal of the American Medical Association
#5
Anika Lucas, Myles Wolf
No abstract text is available yet for this article.
November 8, 2019: JAMA: the Journal of the American Medical Association
#6
Alain Enthoven, Victor R Fuchs, Stephen M Shortell
No abstract text is available yet for this article.
November 7, 2019: JAMA: the Journal of the American Medical Association
#7
Stephen R Baldassarri, David A Fiellin, Abigail S Friedman
No abstract text is available yet for this article.
November 7, 2019: JAMA: the Journal of the American Medical Association
#8
Rebecca Voelker
No abstract text is available yet for this article.
November 6, 2019: JAMA
#9
(no author information available yet)
No abstract text is available yet for this article.
November 6, 2019: JAMA: the Journal of the American Medical Association
#10
Jennifer Abbasi
No abstract text is available yet for this article.
November 6, 2019: JAMA: the Journal of the American Medical Association
#11
Christopher M Jones, Melissa T Merrick, Debra E Houry
No abstract text is available yet for this article.
November 5, 2019: JAMA
#12
Karen A Cullen, Andrea S Gentzke, Michael D Sawdey, Joanne T Chang, Gabriella M Anic, Teresa W Wang, MeLisa R Creamer, Ahmed Jamal, Bridget K Ambrose, Brian A King
Importance: The prevalence of e-cigarette use among US youth increased from 2011 to 2018. Continued monitoring of the prevalence of e-cigarette and other tobacco product use among youth is important to inform public health policy, planning, and regulatory efforts. Objective: To estimate the prevalence of e-cigarette use among US high school and middle school students in 2019 including frequency of use, brands used, and use of flavored products. Design, Setting, and Participants: Cross-sectional analyses of a school-based nationally representative sample of 19 018 US students in grades 6 to 12 participating in the 2019 National Youth Tobacco Survey...
November 5, 2019: JAMA
#13
Adam M Leventhal, Richard Miech, Jessica Barrington-Trimis, Lloyd D Johnston, Patrick M O'Malley, Megan E Patrick
No abstract text is available yet for this article.
November 5, 2019: JAMA
#14
Vijaya L Rao, Dejan Micic, Andrew M Davis
No abstract text is available yet for this article.
November 4, 2019: JAMA: the Journal of the American Medical Association
#15
Arnold Wald
No abstract text is available yet for this article.
November 4, 2019: JAMA: the Journal of the American Medical Association
#16
Cheryl Healton, Robert Pack, Sandro Galea
No abstract text is available yet for this article.
November 1, 2019: JAMA: the Journal of the American Medical Association
#17
Jennifer Abbasi
No abstract text is available yet for this article.
October 31, 2019: JAMA: the Journal of the American Medical Association
#18
Rita Rubin
No abstract text is available yet for this article.
October 31, 2019: JAMA
#19
Anne R Cappola
No abstract text is available yet for this article.
October 30, 2019: JAMA: the Journal of the American Medical Association
#20
Simon P Mooijaart, Robert S Du Puy, David J Stott, Patricia M Kearney, Nicolas Rodondi, Rudi G J Westendorp, Wendy P J den Elzen, Iris Postmus, Rosalinde K E Poortvliet, Diana van Heemst, Barbara C van Munster, Robin P Peeters, Ian Ford, Sharon Kean, Claudia-Martina Messow, Manuel R Blum, Tinh-Hai Collet, Torquil Watt, Olaf M Dekkers, J Wouter Jukema, Johannes W A Smit, Peter Langhorne, Jacobijn Gussekloo
Importance: It is unclear whether levothyroxine treatment provides clinically important benefits in adults aged 80 years and older with subclinical hypothyroidism. Objective: To determine the association of levothyroxine treatment for subclinical hypothyroidism with thyroid-related quality of life in adults aged 80 years and older. Design, Setting, and Participants: Prospectively planned combined analysis of data involving community-dwelling adults aged 80 years and older with subclinical hypothyroidism...
October 30, 2019: JAMA: the Journal of the American Medical Association
Fetching more papers... 
